The upside of being a digital pharma player
Related Experiment Video
Updated: Dec 18, 2025

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology
Published on: June 13, 2025
Alexander Schuhmacher1, Alexander Gatto2, Markus Hinder3
1Reutlingen University, Alteburgstrasse 150, DE-72762 Reutlingen, Germany.
Abstract:
We investigated the state of artificial intelligence (AI) in pharmaceutical research and development (R&D) and outline here a risk and reward perspective regarding digital R&D. Given the novelty of the research area, a combined qualitative and quantitative research method was chosen, including the analysis of annual company reports, investor relations information, patent applications, and scientific publications of 21 pharmaceutical companies for the years 2014 to 2019. As a result, we can confirm that the industry is in an 'early mature' phase of using AI in R&D. Furthermore, we can demonstrate that, despite the efforts that need to be managed, recent developments in the industry indicate that it is worthwhile to invest to become a 'digital pharma player'.
Related Concept Videos
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Drug Discovery: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Prodrugs
Prodrugs help overcome...

